Although sPD-Ll have been recognized as naturally existing regulators of PD-1/PD-L1 membrane signaling pathways in various disease systems, the biological activity of sPD-L1 remains incompletely understood, clearly, further work is needed to better understand the implications of sPD-L1 levels on immunotherapy efficacy in breast cancer. The gene discussed is SPDL1; the disease is breast carcinoma.